Charles L Wiseman
Overview
Explore the profile of Charles L Wiseman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiseman C, Holmes J, Calfa C, Dakhil S, Bhattacharya S, Peoples G, et al.
Hum Vaccin Immunother
. 2024 Aug;
20(1):2379864.
PMID: 39165083
This Phase I/IIa open-label, single-arm clinical trial addressing advanced, refractory, metastatic breast cancer was conducted at six medical centers in the United States. We repeated inoculations with irradiated SV-BR-1-GM, a...
2.
Wiseman C, Kharazi A, Sunkari V, Galeas J, Dozio V, Hashwah H, et al.
Recent Pat Anticancer Drug Discov
. 2022 May;
18(2):224-240.
PMID: 35593340
Background: SV-BR-1-GM, derived from a patient with grade 2 (moderately differentiated) breast cancer, is a GM-CSF-secreting breast cancer cell line with properties of antigen-presenting cells. SV-BR-1-GM and next-generation versions are...
3.
Lacher M, Bauer G, Fury B, Graeve S, Fledderman E, Petrie T, et al.
Front Immunol
. 2018 Jun;
9:776.
PMID: 29867922
Targeted cancer immunotherapy with irradiated, granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting, allogeneic cancer cell lines has been an effective approach to reduce tumor burden in several patients. It is generally assumed that...
4.
Wiseman C, Kharazi A
Breast J
. 2006 Sep;
12(5):475-80.
PMID: 16958969
A patient with recurrent breast cancer metastases following initial response to chemotherapy and hormonal maintenance was treated with a whole-cell tumor vaccine, resulting in a prompt objective complete remission of...
5.
de Pillis L, Radunskaya A, Wiseman C
Cancer Res
. 2005 Sep;
65(17):7950-8.
PMID: 16140967
Mathematical models of tumor-immune interactions provide an analytic framework in which to address specific questions about tumor-immune dynamics. We present a new mathematical model that describes tumor-immune interactions, focusing on...
6.
Kudinov Y, Wiseman C, Kharazi A
Cancer Cell Int
. 2003 Jun;
3:4.
PMID: 12787470
Background: The expression of major histocompatibility complex class II (MHCII) antigens in both mouse and human tumors is rare, and these antigens are not easily inducible by IFN-gamma (IFNg). Since...